Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Core Insights - Barinthus Biotherapeutics plc announced positive results from the Phase 1 trial of VTP-1000 for celiac disease, showing it was well tolerated with no serious adverse events and a dose-dependent pharmacological effect [1][2][6] Company Overview - Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for autoimmune and inflammatory diseases, utilizing its proprietary SNAP-TI platform [5][7] - The company's lead candidate, VTP-1000, aims to restore immune non-responsiveness to gluten in celiac disease patients and is currently in a Phase 1 clinical trial [5][6] Trial Details - The single ascending dose (SAD) portion of the AVALON trial enrolled 18 patients across three placebo-controlled cohorts, demonstrating that VTP-1000 was well tolerated at all dose levels [2][6] - The multiple ascending dose (MAD) portion of the trial, which includes a gluten challenge, is ongoing with results expected in the second half of 2026 [1][6] Disease Context - Celiac disease affects approximately 1 in 100 people globally, leading to an autoimmune response to gluten that can cause significant health issues [4] - There are currently no approved treatments for celiac disease, making the development of VTP-1000 particularly significant [4]